Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.
1. A method of treating hypertension in a cat in need thereof, the method comprising daily administration of a therapeutically effective amount of an angiotensin II receptor 1 (AT-1) antagonist (sartan) or a pharmaceutically acceptable salt thereof to the cat, wherein the sartan is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, and valsartan, and the therapeutically effective amount of the sartan is at least 0.75 mg/kg of body weight and not greater than 5.0 mg/kg of body weight.
2. The method of claim 1 , wherein the sartan is selected from the group consisting of irbesartan, losartan, and telmisartan.
3. The method of claim 1 , wherein the sartan is telmisartan.
4. The method of claim 1 , wherein the method further comprises administration of at least one other drug to the cat in need of such a treatment.
5. The method of claim 4 , wherein the other drug is selected from the group consisting of Ca-channel blockers, beta-blockers, cardiotonic-Ca-sensitising agents, selective If-current inhibitors, ACE inhibitors, and anti-obesity drugs.
6. The method of claim 1 , wherein the daily administration is an oral administration.
7. The method of claim 1 , wherein the daily administration is a rectal administration, a nasal administration or an inhalative administration.
8. The method of claim 1 , wherein the daily administration of the therapeutically effective amount is provided in a single dose.
9. The method of claim 1 , wherein the daily administration of the therapeutically effective amount is provided in a plurality of doses.
10. The method of claim 1 , wherein the therapeutically effective amount of the sartan is administered daily for a treatment period of over 4 weeks.
11. The method of claim 1 , wherein the therapeutically effective amount of the sartan is administered daily for a treatment period comprising a plurality of days, and the daily dosage amount administered to the cat is varied over the treatment period.
12. A method of treating hypertension in a cat in need thereof, the method comprising daily administration of a therapeutically effective amount of an angiotensin II receptor 1 (AT-1) antagonist (sartan) or a pharmaceutically acceptable salt thereof to the cat, wherein the sartan is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, and valsartan, and the therapeutically effective amount of the sartan is at least 0.75 mg/kg of body weight and not greater than 5.0 mg/kg of body weight.